<SEC-DOCUMENT>0001193125-23-170302.txt : 20230621
<SEC-HEADER>0001193125-23-170302.hdr.sgml : 20230621
<ACCEPTANCE-DATETIME>20230620173614
ACCESSION NUMBER:		0001193125-23-170302
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20230621
DATE AS OF CHANGE:		20230620

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			X4 Pharmaceuticals, Inc
		CENTRAL INDEX KEY:			0001501697
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				273181608
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-272551
		FILM NUMBER:		231026627

	BUSINESS ADDRESS:	
		STREET 1:		61 NORTH BEACON STREET
		STREET 2:		4TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02134
		BUSINESS PHONE:		857-529-8300

	MAIL ADDRESS:	
		STREET 1:		61 NORTH BEACON STREET
		STREET 2:		4TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02134

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Arsanis, Inc.
		DATE OF NAME CHANGE:	20100920
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d418143d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>As Filed Pursuant to Rule 424(b)(3) <BR>Registration No. 333-272551 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g418143g93w91.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>42,784,203 Shares of Common Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Offered by the Selling Stockholders </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to the resale from time to time of up to 42,784,203 shares of common stock, par value $0.001 per share, of X4
Pharmaceuticals, Inc. (the &#147;Common Stock&#148;) by the selling stockholders listed on page 10 (the &#147;Selling Stockholders&#148;), including their pledgees, assignees, donees, transferees or their respective <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">successors-in-interest,</FONT></FONT> which consist of (i) 34,521,046 outstanding shares of our Common Stock held by the Selling Stockholders and (ii) 8,263,157 shares of our Common Stock issuable upon the exercise of
outstanding <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase shares of our Common Stock held by the Selling Stockholders. We will not receive any proceeds from the sale of the shares offered by this prospectus, except the
exercise price of $0.001 per share of any of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants exercised for cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
agreed, pursuant to a registration rights agreement that we have entered into with the Selling Stockholders, to bear all of the expenses incurred in connection with the registration of these shares. The Selling Stockholders will pay or assume
discounts, commissions, fees of underwriters, selling brokers or dealer managers and similar expenses, if any, incurred for the sale of these shares of our Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Stockholders identified in this prospectus, or their pledgees, assignees, donees, transferees or their respective <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest,</FONT></FONT> may offer the shares from time to time on terms to be determined at the time of sale through ordinary brokerage transactions or through any other means
described in this prospectus under the caption &#147;Plan of Distribution.&#148; The shares may be sold at fixed prices, at prevailing market prices, at prices related to prevailing market prices or at negotiated prices. For a list of the Selling
Stockholders, see the section entitled &#147;Selling Stockholders&#148; on page 10. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may amend or supplement this prospectus from time
to time by filing amendments or supplements as required. You should read the entire prospectus and any amendments or supplements carefully before you make your investment decision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Common Stock is traded on the Nasdaq Capital Market under the symbol &#147;XFOR.&#148; On June&nbsp;16, 2023, the last reported sale price
of our Common Stock was $2.16 per share. You are urged to obtain current market quotations for our Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:12pt; font-family:Times New Roman"><B>Investing in our
Common Stock involves a high degree of risk. You should carefully read and consider the section entitled &#147;</B><B><I><A HREF="#toc2418143_5">Risk Factors</A></I></B><B>&#148; on page 8, the risk factors included in our periodic reports filed
with the Securities and Exchange Commission (&#147;SEC&#148;), in any applicable prospectus supplement and in any other documents we file with the SEC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR
DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this
prospectus is June&nbsp;20, 2023. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc2418143_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc2418143_2">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc2418143_3">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc2418143_4">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc2418143_5">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc2418143_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc2418143_7">SELLING STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc2418143_8">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc2418143_9">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc2418143_10">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc2418143_11">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc2418143_12">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc2418143_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We urge you to read carefully this prospectus, together with the information incorporated herein by reference as described under the heading
&#147;Where You Can Find Additional Information,&#148; before buying any of the securities being offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the
information contained or incorporated by reference in this prospectus and the applicable prospectus supplement or in any amendment to this prospectus. Neither we nor the Selling Stockholders have authorized anyone to provide you with different
information, and if anyone provides, or has provided you, with different or inconsistent information, you should not rely on it. The Selling Stockholders are offering to sell, and seeking offers to buy, shares of our Common Stock only in
jurisdictions where offers and sales are permitted. The information contained in this prospectus, as well as the information filed previously with the SEC, and incorporated herein by reference, is accurate only as of the date of the document
containing the information, regardless of the time of delivery of this prospectus or any applicable prospectus supplement or any sale of our Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus supplement may add to, update or change the information contained in this prospectus. You should read both this prospectus and
any applicable prospectus supplement together with additional information described below under the heading &#147;Where You Can Find Additional Information.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this prospectus, references to &#147;X4 Pharmaceuticals,&#148; &#147;X4,&#148; the &#147;Company,&#148; the &#147;registrant,&#148;
&#147;we,&#148; &#147;us,&#148; and &#147;our&#148; refer to X4 Pharmaceuticals, Inc., formerly Arsanis, Inc., and its subsidiaries. The phrase &#147;this prospectus&#148; refers to this prospectus and any applicable prospectus supplement, unless
the context requires otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc2418143_2"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and any applicable prospectus supplement or free writing prospectus, including the documents incorporated by reference herein
and therein, contain forward-looking statements. These are based on our management&#146;s current beliefs, expectations and assumptions about future events, conditions and results and on information currently available to us. Discussions containing
these forward-looking statements may be found, among other places, in the sections entitled &#147;Business,&#148; &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148;
contained in the documents incorporated by reference herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any statements in this prospectus, or incorporated herein, about our
expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. Within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended (the &#147;Securities
Act&#148;), and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended (&#147;the Exchange Act&#148;), these forward-looking statements include statements regarding: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, timing, progress and results of our current and future preclinical studies and clinical trials
and related preparatory work and the period during which the results of the trials will become available, as well as our research and development programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential benefits, including clinical utility, that may be derived from any of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of and our ability to obtain and maintain regulatory approval of our existing product candidates or
any product candidates that we may develop in the future, and any related restrictions, limitations, or warnings in the label of any approved product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans to research, develop, manufacture and commercialize our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of our regulatory filings for our product candidates, along with regulatory developments in the United
States and other foreign countries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size and growth potential of the markets for our product candidates, if approved, and the rate and degree of
market acceptance of our product candidates, including reimbursement that may be received from payors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the benefits of U.S. Food and Drug Administration and European Commission designations, including, without
limitation, Fast Track, Orphan Drug and Breakthrough Therapy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our commercialization, marketing and manufacturing capabilities and strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain qualified employees and key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitive position and the development of and projections relating to our competitors or our industry;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding our ability to obtain and maintain intellectual property protection;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of competing therapies that are or may become available; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates and expectations regarding future operations, financial position, revenues, costs, expenses, uses
of cash, capital requirements or our need for additional financing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to continue as a going concern; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans to <FONT STYLE="white-space:nowrap">in-license,</FONT> acquire, develop and commercialize additional
product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of laws and regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans to identify additional product candidates with significant commercial potential that are consistent
with our commercial objectives; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to raise additional capital; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our strategies, prospects, plans, expectations or objectives; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other risks and uncertainties, including those listed under the caption &#147;Risk Factors&#148; in our most
recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> our most recent Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> and other filings we make with the SEC. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some cases, you can identify forward-looking statements by terms such as &#147;may,&#148; &#147;will,&#148; &#147;intend,&#148;
&#147;should,&#148; &#147;could,&#148; &#147;would,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;project,&#148; &#147;predict,&#148; &#147;potential,&#148; &#147;continue,&#148;
&#147;likely,&#148; and similar expressions (including their use in the negative) intended to identify forward-looking statements. These forward-looking statements reflect our current views with respect to future events and are based on assumptions
and subject to risks and uncertainties. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. We discuss many of these risks in greater detail under the heading &#147;Risk Factors&#148; in our
SEC filings, and may provide additional information in any applicable prospectus supplement. Also, these forward-looking statements represent our estimates and assumptions only as of the date of the document containing the applicable statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We qualify all of the forward-looking statements in the foregoing documents by these cautionary statements. Unless required by law, we
undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or
implied in such forward-looking statements. Before deciding to purchase our Common Stock, you should carefully consider the risk factors incorporated by reference herein, in addition to the other information set forth in this prospectus and in the
documents incorporated by reference herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc2418143_3"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights important features of this offering and the information included or incorporated by reference in this prospectus.
This summary does not contain all of the information you should consider before investing in our Common Stock. You should carefully read this prospectus, any applicable prospectus supplement and the information incorporated by reference in this
prospectus and any applicable prospectus supplement before you invest in our Common Stock. </I></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Company Overview </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a late clinical-stage biopharmaceutical company discovering and developing novel therapeutics for the treatment of rare diseases and
those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead clinical
candidate is mavorixafor, a small molecule antagonist of chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. Due to its ability to increase the mobilization of mature, functional white blood cells from the bone marrow
into the bloodstream, we believe that mavorixafor has the potential to provide therapeutic benefit across a variety of chronic neutropenic disorders, including WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome, a rare,
primary immunodeficiency. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2022, we announced positive <FONT STYLE="white-space:nowrap">top-line</FONT> data from our global,
pivotal, Phase 3 clinical trial, referred to as the 4WHIM trial, evaluating the safety and efficacy of mavorixafor in people with WHIM syndrome. In May 2023, we announced additional data from the 4WHIM trial, focusing on the impact of mavorixafor on
the rate, severity and duration of infections in trial participants. We are currently preparing a U.S. New Drug Application (&#147;NDA&#148;) seeking approval of oral, once-daily mavorixafor in the treatment of people aged 12 years and older with
WHIM syndrome. This NDA submission is expected early in the second half of 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mavorixafor has received multiple special designations
from global regulatory authorities in WHIM syndrome, including Breakthrough Therapy Designation, Fast Track Designation, and Rare Pediatric Designation in the United States, and Orphan Drug Status in both the United States and European Union. In
addition, upon approval of an NDA, we are eligible to receive a Priority Review Voucher as a result of mavorixafor&#146;s Rare Pediatric Designation in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also currently advancing mavorixafor in a Phase 2 clinical trial in people with certain chronic neutropenic disorders following
positive results from a Phase 1b clinical trial of mavorixafor in people with idiopathic, cyclic, or congenital neutropenia. Participants are now being enrolled in this Phase 2 clinical trial and we expect to provide an update on clinical results in
the second or third quarter of 2023. We also expect to provide clarity on the scope and timing of our planned Phase 3 chronic neutropenia clinical program in the second or third quarter of 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have not generated revenue from product sales and do not expect to generate significant revenue from the sale of our products in
the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval, we may generate revenue in the future from product sales. We cannot predict if, when, or to what extent we will generate
revenue from the commercialization and sale of our product candidates. We may never succeed in obtaining regulatory approval for any of our product candidates. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Private Placement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Securities Purchase Agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
May&nbsp;15, 2023, we entered into a Securities Purchase Agreement (the &#147;Purchase Agreement&#148;) with the purchasers named therein (the &#147;Purchasers&#148;), pursuant to which we agreed to sell and issue to the Purchasers in a private
placement (the &#147;Private Placement&#148;) (i) an aggregate of 34,521,046 shares of Common Stock at a purchase price of $1.52 per share, which represents the closing price of the Common Stock reported on the Nasdaq Capital Market on May&nbsp;15,
2023, and (ii)&nbsp;with respect to certain Purchasers, in lieu of such shares of Common Stock, <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants (the <FONT STYLE="white-space:nowrap">&#147;Pre-Funded</FONT> Warrants&#148;) to purchase an
aggregate of 8,263,157 shares of Common Stock at a purchase price of $1.519 per <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant. On May&nbsp;18, 2023, we closed the Private Placement and issued an aggregate of 34,521,046 shares of Common
Stock and <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to purchase an aggregate of 8,263,157 shares of Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant has an exercise price equal to $0.001 per share. The <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants are exercisable at any time after their original issuance and will not expire until
exercised in full. The <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants provide that a holder of <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants will not have the right to exercise any portion of its <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants if such holder, together with its affiliates, would beneficially own in excess of 4.99% or 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such
exercise (the &#147;Beneficial Ownership Limitation&#148;); provided, however, that each holder may increase or decrease the Beneficial Ownership Limitation by giving 61 days&#146; notice to us, but not to any percentage in excess of 19.99%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of Common Stock issued to the Purchasers, and the shares of Common Stock issuable upon the exercise of the <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, were not initially registered under the Securities Act or any state securities laws. We have relied on the exemption from the registration requirements afforded by Regulation D under the
Securities Act. In connection with their execution of the Purchase Agreement, each of the Purchasers represented to us that such Purchaser is an &#147;accredited investor&#148; as defined in Regulation D of the Securities Act and that the securities
purchased by such Purchaser were being acquired solely for its own account and for investment purposes and not with a view to its future sale or distribution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Registration Rights Agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
May&nbsp;15, 2023, in connection with the Private Placement, we entered into a Registration Rights Agreement with the Purchasers (the &#147;Registration Rights Agreement&#148;), pursuant to which we agreed to (i)&nbsp;promptly following the closing
date of the Private Placement, and in no event later than thirty (30)&nbsp;days from the date of the Registration Rights Agreement, file a registration statement with the SEC to cover the resale of the shares of Common Stock, including those shares
of Common Stock issuable upon exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, issued to the Purchasers pursuant to the Purchase Agreement (collectively, the &#147;Shares&#148;), (ii) to use commercially reasonable
efforts to cause such registration statement to become effective as soon as practicable and (iii)&nbsp;to keep such registration statement effective until the date the Shares covered by such registration statement have been sold or may be resold
pursuant to Rule 144 without restriction. In the event that such registration statement is not filed or declared effective within the timeframes set forth in the Registration Rights Agreement or, after the registration statement has been declared
effective by the SEC, sales cannot be made pursuant to the registration statement for any reason including by reason of a stop order or our failure to update such registration statement, subject to certain limited exceptions, then we have agreed to
make pro rata payments to each Purchaser as liquidated damages in an amount equal to 1% of the aggregate amount invested by each such Purchaser in the Shares per <FONT STYLE="white-space:nowrap">30-day</FONT> period or pro rata for any portion
thereof for each such month during which such event continues, subject to certain caps set forth in the Registration Rights Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registration statement of which this prospectus is a part relates to the offer and resale of the shares of Common Stock issued to the
Purchasers pursuant to the Purchase Agreement, including the shares issuable upon exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. When we refer to the Selling Stockholders in this prospectus, we are
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
referring to the Purchasers named in this prospectus as the Selling Stockholders and, as applicable, any donees, pledgees, assignees, transferees or other <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> selling the Shares received after the date of this prospectus from the Selling Stockholders as a gift, pledge, or other <FONT STYLE="white-space:nowrap">non-sale</FONT> related
transfer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to March&nbsp;13, 2019, we were a clinical-stage biopharmaceutical company known as Arsanis, Inc. that had historically been focused on
applying monoclonal antibody immunotherapies to address serious infectious diseases. Arsanis, Inc. was originally incorporated in the State of Delaware in August 2010. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;13, 2019, we completed our business combination with X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) in accordance
with the terms of an Agreement and Plan of Merger, dated as of November&nbsp;26, 2018, as amended on December&nbsp;20, 2018 and March&nbsp;8, 2019 (the &#147;Merger Agreement&#148;), that we entered into with X4 Therapeutics, Inc. and Artemis AC
Corp., a Delaware corporation and our wholly owned subsidiary (&#147;Merger Sub&#148;). Pursuant to the terms of the Merger Agreement, Merger Sub merged with and into X4 Therapeutics, Inc., with X4 Therapeutics, Inc. continuing as our wholly owned
subsidiary and the surviving corporation of the merger, which transaction we refer to as the Merger. At the closing of the Merger, we issued shares of our Common Stock to X4 Therapeutics, Inc. stockholders based on an agreed upon exchange ratio, and
each option or warrant to purchase X4 Therapeutics, Inc. capital stock became an option or warrant, respectively, to purchase our Common Stock, subject to adjustment in accordance with the agreed upon exchange ratio. Following the closing of the
Merger, we effected a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-6</FONT></FONT> reverse stock split of our Common Stock, our name was changed to X4 Pharmaceuticals, Inc., the business of X4 Therapeutics, Inc. became our
business, and we became a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases. In connection with the closing of the Merger, our stock began
trading on the Nasdaq Capital Market under the symbol &#147;XFOR&#148; on March&nbsp;14, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive offices are
located at 61 North Beacon Street, 4th Floor, Boston, Massachusetts 02134, and our telephone number is (857) <FONT STYLE="white-space:nowrap">529-8300.</FONT> Our website is located at http://www.x4pharma.com. We do not incorporate by reference into
this prospectus the information on, or accessible through, our website, and you should not consider it as part of this prospectus. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc2418143_4"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common Stock Offered by the Selling Stockholders </P></TD>
<TD>Up to 42,784,203 Shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of Proceeds </P></TD>
<TD>We will not receive any proceeds from the sale of the Shares covered by this prospectus, except with respect to amounts received by us due to the exercise of <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq Capital Market Symbol </P></TD>
<TD>XFOR </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc2418143_5"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An investment in our Common Stock involves a high degree of risk. Prior to making a decision about investing in our Common Stock, you should
consider carefully the specific risk factors discussed in the sections entitled &#147;Risk Factors&#148; contained in our most recent Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March&nbsp;31, 2023, as
filed with the SEC on May&nbsp;4, 2023, which are incorporated in this prospectus by reference in their entirety, as well as any amendment or updates to our risk factors reflected in subsequent filings with the SEC, including any prospectus
supplement hereto. These risks and uncertainties are not the only risks and uncertainties we face. Additional risks and uncertainties not presently known to us, or that we currently view as immaterial, may also impair our business. If any of the
risks or uncertainties described in our SEC filings or any additional risks and uncertainties actually occur, our business, financial condition, results of operations and cash flow could be materially and adversely affected. In that case, the
trading price of our Common Stock could decline and you might lose all or part of your investment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc2418143_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are filing the registration statement of which this prospectus forms a part to permit the holders of the Shares of our Common Stock
described in the section entitled &#147;Selling Stockholders&#148; to resell such Shares. We are not selling any securities under this prospectus, and we will not receive any proceeds from the sale or other disposition of shares of our Common Stock
held by the Selling Stockholders, except with respect to amounts received by us due to the exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Stockholders will pay any underwriting discounts and commissions and expenses incurred by the Selling Stockholders for brokerage,
accounting, tax or legal services or any other expenses incurred by the Selling Stockholders in disposing of these Shares. We will bear all other costs, fees and expenses incurred in effecting the registration of the Shares covered by this
prospectus, including, without limitation, all registration and filing fees, Nasdaq listing fees and fees and expenses of our counsel and our accountants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc2418143_7"></A>SELLING STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus covers the sale or other disposition by the Selling Stockholders of up to the total number of shares of our Common Stock that
were issued to the Selling Stockholders pursuant to the Purchase Agreement, plus the total number of shares of our Common Stock issuable upon exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants issued to the Selling
Stockholders pursuant to the Purchase Agreement, without giving effect to the Beneficial Ownership Limitation described under &#147;Prospectus Summary&#151;Private Placement&#151;Securities Purchase Agreement.&#148; The table below sets forth, to
our knowledge, information concerning the beneficial ownership of shares of our Common Stock by the Selling Stockholders as of May&nbsp;19, 2023. The information in the table below with respect to the Selling Stockholders has been obtained from the
respective Selling Stockholders. When we refer to the &#147;Selling Stockholders&#148; in this prospectus, or, if required, a post-effective amendment to the registration statement of which this prospectus is a part, we mean the Selling Stockholders
listed in the table below as offering Shares, as well as their respective pledgees, assignees, donees, transferees or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest.</FONT></FONT> Throughout this prospectus,
when we refer to the shares of our Common Stock being registered on behalf of the Selling Stockholders, we are referring to the shares of our Common Stock and the shares underlying the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants
issued to the Selling Stockholders pursuant to the Purchase Agreement, without giving effect to the Beneficial Ownership Limitation described above. The Selling Stockholders may sell all, some or none of the shares of Common Stock subject to this
prospectus. See &#147;Plan of Distribution&#148; below as it may be supplemented and amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of
Common Stock beneficially owned prior to the offering for each Selling Stockholder includes all shares of our Common Stock beneficially held by such Selling Stockholder as of May&nbsp;19, 2023, which includes (i)&nbsp;all shares of our Common Stock
purchased by such Selling Stockholder in the Private Placement and (ii)&nbsp;all shares of Common Stock issuable upon exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants purchased by such Selling Stockholder in the Private
Placement, subject to the Beneficial Ownership Limitation described under &#147;Prospectus Summary&#151;Private Placement&#151;Securities Purchase Agreement.&#148; The percentages of shares owned before and after the offering are based on
158,684,870 shares of Common Stock outstanding as of May&nbsp;19, 2023, which includes the outstanding shares of Common Stock offered by this prospectus but does not include any shares of Common Stock offered by this prospectus that are issuable
pursuant to the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and are deemed outstanding in the table below because they are beneficially owned by a Selling Stockholder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than as stated above, beneficial ownership is determined in accordance with the rules of the SEC and includes voting or investment power
with respect to our Common Stock. Generally, a person &#147;beneficially owns&#148; shares of our Common Stock if the person has or shares with others the right to vote those shares or to dispose of them, or if the person has the right to acquire
voting or disposition rights within 60 days. In computing the number of shares of our Common Stock beneficially owned by a Selling Stockholder and the percentage ownership of such Selling Stockholder, we deemed outstanding shares of Common Stock
issuable upon the exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants (regardless of whether or not such <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants were acquired in the Private Placement) and/or warrants, as
applicable, held by that Selling Stockholder that are exercisable within 60&nbsp;days of May&nbsp;19, 2023. We did not deem these shares outstanding, however, for the purpose of computing the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
percentage ownership of any other Selling Stockholder. The inclusion of any shares in this table does not constitute an admission of beneficial ownership for any Selling Stockholder named below.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares of</B><br><B>Common Stock</B><br><B>Beneficially Owned</B><br><B>Prior to Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares of</B><br><B>Common Stock</B><br><B>to be Beneficially</B><br><B>Owned After</B><br><B>Offering(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Selling Stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of</B><br><B>Shares of</B><br><B>Common Stock</B><br><B>Being&nbsp;Offered(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Bain Capital Life Sciences(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,195,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,289,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,560,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Growth Equity Opportunities 18 VGE, LLC(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,948,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,223,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,861,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OrbiMed Private Investments IV, LP(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,494,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,315,789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,178,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Acorn Bioventures(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,950,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,289,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,123,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Empery Asset Management LP(7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,181,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,631,577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,549,606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Integrated Core Strategies (US) LLC(8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,310,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,973,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,336,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Tri Locum(9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,672,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,947,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,725,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CVI Investments, Inc.(10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,660,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,350,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,310,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stonepine Capital, LP(11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,605,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,605,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adage Capital Partners LP(12)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,276,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,276,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Schonfeld EXT Master Fund LP(13)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,431,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">909,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,522,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Parkman HP Master Fund LP(14)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,577,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">340,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,236,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lytton-Kambara Foundation(15)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,151,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">657,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,493,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citadel CEMF Investments Ltd.(16)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Kingdon(17)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,973,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,973,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Less than one percent. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The number of shares of our Common Stock in the column &#147;Number of Shares of Common Stock Being
Offered&#148; represents all of the shares of our Common Stock that a Selling Stockholder may offer and sell from time to time under this prospectus. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We do not know when or in what amounts a Selling Stockholder may offer shares for sale. The Selling
Stockholders might not sell any or might sell all of the shares offered by this prospectus. Because the Selling Stockholders may offer all or some of the shares pursuant to this offering, and because there are currently no agreements, arrangements
or understandings with respect to the sale of any of the shares, we cannot estimate the number of the shares that will be held by the Selling Stockholders after completion of the offering. However, for purposes of this table, we have assumed that,
after completion of the offering, none of the shares covered by this prospectus will be held by the Selling Stockholders, including Common Stock issuable upon exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants issued in the
Private Placement. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#147;Shares of Common Stock Beneficially Owned Prior to the Offering&#148; consist
of (i) 968,012 and 2,321,461 shares of Common Stock purchased by BCLS I Investco, LP (&#147;BCLS Investco I&#148;) and BCLS II Investco, LP (&#147;BCLS Investco II&#148;), respectively, in the Private Placement, (ii) 2,522,176 additional shares of
Common Stock previously purchased by BCLS Investco I, (iii) 6,948,620 additional shares of Common Stock previously purchased by BCLS Investco II, and (iv)&nbsp;an aggregate of 3,435,562 shares of Common Stock issuable to BCLS Investco I and BCLS
Investco II upon the exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and/or warrants held by BCLS Investco I and BCLS Investco II. In addition to the foregoing shares, as of May&nbsp;19, 2023, BCLS Investco I and BCLS
Investco II held <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and warrants to purchase an aggregate of 17,820,064 shares of Common Stock, which are not included in the shares reported under &#147;Shares of Common Stock Beneficially
Owned Prior to the Offering&#148; because they are </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
subject to limitations on exercisability if such exercise would result in BCLS Investco I or BCLS Investco II beneficially owning more than 9.99% of our outstanding Common Stock. The shares
reported under &#147;Number of Shares of Common Stock Being Offered&#148; consist of 968,012 and 2,321,461 shares of Common Stock purchased by BCLS Investco I and BCLS Investco II, respectively, in the Private Placement. The shares reported under
&#147;Number of Shares of Common Stock to be Beneficially Owned After Offering&#148; consist of (i) 2,522,176 shares of Common Stock held by BCLS Investco I, (ii) 6,948,620 shares of Common Stock held by BCLS Investco II and (iii)&nbsp;an aggregate
of 7,090,126 shares of Common Stock issuable to BCLS Investco I and BCLS Investco II upon the exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and/or warrants held by BCLS Investco I and BCLS Investco II.. Bain Capital Life
Sciences Investors, LLC (&#147;BCLSI&#148;) is the ultimate general partner of each of BCLS Investco I and BCLS Investco II. As a result, BCLSI may be deemed to share voting and dispositive power with respect to the shares of Common Stock
beneficially owned by each of BCLS Investco I and BCLS Investco II. The address of each of BCLS Investco I and BCLS Investco II is c/o Bain Capital Life Sciences, LP, 200 Clarendon Street, Boston, MA 02116. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#147;Shares of Common Stock Beneficially Owned Prior to the Offering&#148; consist
of (i) 3,250,000 shares of Common Stock purchased in the Private Placement, (ii)&nbsp;an aggregate of 11,736,793 additional shares of Common Stock previously purchased and (iii) 961,921 shares of Common Stock issuable upon the exercise of the <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants purchased in the Private Placement. The shares underlying the following <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and warrants are not included in the shares reported under
&#147;Shares of Common Stock Beneficially Owned Prior to the Offering&#148; because they are subject to limitations on exercisability if such exercise would result in Growth Equity Opportunities 18 VGE, LLC beneficially owning more than 4.99% or
9.99% of our outstanding Common Stock: (a) 4,011,763 shares of Common Stock issuable upon exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants purchased in the Private Placement, (b) 13,332,032 shares of Common Stock issuable
upon exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants previously purchased, (c) 13,705,189 shares of Common Stock issuable upon the exercise of warrants previously purchased and (d) 5,681,818 shares of Common Stock issuable
upon the exercise of our Class&nbsp;C warrants, two of which are exercisable into one share of Common Stock, previously purchased. The shares reported under &#147;Number of Shares of Common Stock Being Offered&#148; consist of the shares of Common
Stock, including the shares of Common Stock issuable upon exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, purchased by Growth Equity Opportunities 18 VGE, LLC in the Private Placement, without giving effect to the
Beneficial Ownership Limitation. The shares reported under &#147;Number of Shares of Common Stock to be Beneficially Owned After Offering&#148; consist of (i)&nbsp;an aggregate of 11,736,793 shares of Common Stock held by Growth Equity Opportunities
18 VGE, LLC prior to the Private Placement and (ii) 5,124,649 shares of Common Stock issuable upon the exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants previously purchased by Growth Equity Opportunities 18 VGE, LLC, excluding
shares underlying the other <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and warrants that are not exercisable due to the Beneficial Ownership Limitation. Growth Equity Opportunities 18 VGE, LLC is wholly owned by NEA 18 Venture
Growth Equity, L.P. (&#147;NEA 18 VGE&#148;). The sole general partner of NEA 18 VGE is NEA Partners 18 VGE, L.P. (&#147;NEA Partners 18 VGE&#148;). The sole general partner of NEA Partners 18 VGE is NEA VGE 18 GP, LLC (&#147;NEA VGE 18 LLC&#148;).
The managers of NEA VGE 18 are Scott D. Sandell, Anthony A. Florence, Jr., Mohamad Makhzoumi, Ali Behbahani, Carmen Chang, Edward T. Mathers, Paul E. Walker and Rick C. Yang. NEA VGE 18 and its managers may be deemed to beneficially own the
securities held by Growth Equity Opportunities 18 VGE, LLC. Each of NEA VGE 18 and its managers disclaims beneficial ownership of any of the shares of our Common Stock they may be deemed to beneficially own except to the extent of their respective
pecuniary interest therein. The address of Growth Equity Opportunities 18 VGE, LLC, NEA 18 VGE, NEA Partners 18 VGE, NEA VGE 18 and Scott Sandell is New Enterprise Associates, 1954 Greenspring Drive, Suite 600, Timonium, MD 21093.The address of the
principal business office of Ali Behbahani and Edward Mathers is New Enterprise Associates, 5425 Wisconsin Avenue, Suite 800, Chevy Chase, MD 20815. The address of the principal business office of Carmen Chang, Mohamad Makhzoumi, Paul Walker and
Rick Yang is New Enterprise Associates, 2855 Sand Hill Road, Menlo Park, California 94025. The address of the principal business office of Florence is New Enterprise Associates, 104 5th Avenue, 19th Floor, New York, NY 10001. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#147;Shares of Common Stock Beneficially Owned Prior to the Offering&#148; consist
of (i) 1,315,789 shares of Common Stock purchased by OrbiMed Private Investments IV, LP (&#147;OPI IV&#148;) in the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Private Placement, (ii) 7,133,515 additional shares of Common Stock previously purchased by OPI IV and (iii)&nbsp;an aggregate of 4,360,922 shares of Common Stock issuable upon exercise of
certain warrants previously purchased by OPI IV. OrbiMed Capital GP IV LLC (&#147;GP IV&#148;) is the general partner of OPI IV. OrbiMed Advisors LLC (&#147;OrbiMed Advisors&#148;) is the managing member of GP IV. By virtue of such relationships, GP
IV and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI IV and as a result, may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power
through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild. Each of Messrs. Gordon, Borho, and Neild disclaims beneficial ownership of the shares held by OPI IV, except to the extent of their respective pecuniary
interest therein. Dr.&nbsp;Gordon previously was a member of our Board of Directors. The address for each of OPI IV, GP IV, OrbiMed Advisors, and Messrs. Gordon, Borho, and Neild is c/o OrbiMed Advisors LLC, 601 Lexington Avenue, 54th Floor, New
York, NY 10022. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#147;Shares of Common Stock Beneficially Owned Prior to the Offering&#148; consist
of (i) 3,046,472 shares of Common Stock previously purchased by Acorn Bioventures I, (ii) 4,264,178 shares of Common Stock previously purchased by Acorn Bioventures II (together with Acorn Bioventures I, the &#147;Acorn Bioventures Entities&#148;)
and (iii) 639,643 shares of Common Stock issuable upon exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants purchased by Acorn Bioventures I in the Private Placement. The shares underlying the following <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants purchased in the Private Placement are not included in the shares reported under &#147;Shares of Common Stock Beneficially Owned Prior to the Offering&#148; because they are subject to
limitations on exercisability if such exercise would result in the Acorn Bioventures entities beneficially owning more than 4.99% of our outstanding Common Stock: (a) 741,936 shares of Common Stock issuable upon exercise of the <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants purchased by Acorn Bioventures I in the Private Placement and (b) 1,907,894 shares of Common Stock issuable upon exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants
purchased by Acorn Bioventures II in the Private Placement. In addition, the shares underlying the following <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and warrants (collectively, the &#147;Previous Acorn Warrants&#148;) previously
purchased by the Acorn Bioventures Entities are not included in the shares reported under &#147;Shares of Common Stock Beneficially Owned Prior to the Offering&#148; because they are subject to limitations on exercisability if such exercise would
result in the Acorn Bioventures Entities beneficially owning more than 4.99% of our outstanding Common Stock: (a) 137,112 shares of Common Stock issuable upon the exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants previously
purchased by Acorn Bioventures I, (b) 189,344 shares of Common Stock issuable upon the exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants previously purchased by Acorn Bioventures II, (c) 2,876,837 shares of Common Stock
issuable upon the exercise of warrants previously purchased by Acorn Bioventures I, (d) 3,972,776 shares of Common Stock issuable upon the exercise of warrants previously purchased by Acorn Bioventures II, (e) 763,636 shares of Common Stock issuable
upon the exercise of our Class&nbsp;C warrants, two of which are exercisable into one share of Common Stock, previously purchased by Acorn Bioventures I and (f) 1,054,546 shares of Common Stock issuable upon the exercise of our Class&nbsp;C
warrants, two of which are exercisable into one share of Common Stock, previously purchased by Acorn Bioventures II. The shares reported under &#147;Number of Shares of Common Stock Being Offered&#148; represent the shares of Common Stock issuable
upon exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants purchased by the Acorn Bioventures Entities in the Private Placement without giving effect to the Beneficial Ownership Limitation. The shares reported under
&#147;Shares of Common Stock Beneficially Owned After the Offering&#148; include 812,409 shares of Common Stock issuable upon exercise of the Previous Acorn Warrants that would be exercisable following the disposition by the Acorn Bioventures
Entities of all of the shares registered for sale under this prospectus, giving effect to the Beneficial Ownership Limitation of 4.99%. Isaac Manke and Anders Hove have voting and investment control over the shares of Common Stock held by Acorn
Bioventures I and Acorn Bioventures II. Isaac Manke and Anders Hove have voting and investment control over the shares of Common Stock held by Acorn Bioventures I and Acorn Bioventures II. The address of Acorn Bioventures I and Acorn Bioventures II
is 420 Lexington Ave, Suite 2626, New York, NY 11027. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#147;Shares of Common Stock Beneficially Owned Prior to the Offering&#148; consist
of (i) 1,500,803 shares of Common Stock purchased by Empery Asset Master, LTD (&#147;EAM&#148;) in the Private Placement, (ii) 486,476 shares of Common Stock purchased by Empery Tax Efficient, LP (&#147;ETE&#148;) in the Private Placement, (iii)
644,298 shares of Common Stock purchased by Empery Tax Efficient III, LP (&#147;ETE </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
III&#148;) in the Private Placement, (iv) 499,826 shares of Common Stock issuable upon the exercise of warrants previously purchased by EAM, (v) 150,746 shares of Common Stock issuable upon the
exercise of warrants previously purchased by ETE, (vi) 262,670 shares of Common Stock issuable upon the exercise of warrants previously purchased by ETE III, (vii) 2,405,070 shares of Common Stock issuable upon the exercise of our Class&nbsp;C
warrants, two of which are exercisable into one share of Common Stock, previously purchased by EAM, (viii) 733,617 shares of Common Stock issuable upon the exercise of our Class&nbsp;C warrants previously purchased by ETE and (ix) 497,677 shares of
Common Stock issuable upon the exercise of our Class&nbsp;C warrants previously purchased by ETE III. Empery Asset Management LP, the authorized agent of each of EAM, ETE and ETE III, has discretionary authority to vote and dispose of the securities
held by EAM, ETE and ETE III, as applicable, and may be deemed to be the beneficial owner of such securities. Martin Hoe and Ryan Lane, in their capacity as investment managers of Empery Asset Management LP, may also be deemed to have investment
discretion and voting power over the securities held by EAM, ETE and ETE III. EAM, ETE, ETE III, Mr.&nbsp;Hoe and Mr.&nbsp;Lane each disclaim any beneficial ownership of such securities. The address of each of EAM, ETE, ETE III, Empery Asset
Management LP, Mr.&nbsp;Hoe and Mr.&nbsp;Lane is c/o Empery Asset Management, LP, One Rockefeller Plaza, Suite 1205, New York City, NY 10020. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#147;Shares of Common Stock Beneficially Owned Prior to the Offering&#148; consist
of (i) 1,973,684 shares of Common Stock purchased by Integrated Core Strategies (US) LLC in the Private Placement, (ii) 2,811,069 additional shares of Common Stock previously purchased by Integrated Core Strategies (US) LLC, (iii) 418,390 shares of
Common Stock, 161,912 shares of Common Stock, 892,086 shares of Common Stock, 625 shares of Common Stock and 52,676 shares of Common Stock held by ICS Opportunities II LLC, ICS Opportunities, Ltd., Integrated Assets II LLC, Integrated Assets III LLC
and Integrated Assets, Ltd., respectively, all of which are affiliates of Integrated Core Strategies (US) LLC. The securities listed above may be deemed to be beneficially owned by Millennium Management LLC, Millennium Group Management LLC and
Israel Englander and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr.&nbsp;Englander (the sole voting trustee of the managing member of Millennium Group
Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr.&nbsp;Englander as to the beneficial ownership of the securities held by such entities. The
address for Integrated Core Strategies (US) LLC is c/o Millennium Management LLC, 399 Park Avenue, New York, New York 10022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#147;Shares of Common Stock Beneficially Owned Prior to the Offering&#148; consist
of (i) 839,921 shares of Common Stock purchased by Tri Locum Healthcare Master Fund LP (&#147;Tri Locum Master Fund&#148;) in the Private Placement, (ii) 2,035,934 shares of Common Stock purchased by New Holland Tactical Alpha Fund LP (&#147;New
Holland&#148;) in the Private Placement, (iii) 1,071,513 shares of Common Stock purchased by 405 MSTV I LP (&#147;MSTV I&#148;), (iv) 125,905 additional shares of Common Stock held by Tri Locum Master Fund, (v) 305,182 additional shares of Common
Stock held by New Holland, (vi) 160,629 additional shares of Common Stock held by MSTV I, (vii) 303,052 shares of Common Stock issuable upon the exercise of our Class&nbsp;C warrants, two of which are exercisable into one share of Common Stock, held
by Tri Locum Master Fund, (viii) 543,963 shares of Common Stock issuable upon the exercise of our Class&nbsp;C warrants, two of which are exercisable into one share of Common Stock, held by New Holland and (ix) 286,682 shares of Common Stock
issuable upon the exercise of our Class&nbsp;C warrants, two of which are exercisable into one share of Common Stock, held by MSTV I. Prashanth Jayaram, CEO of Tri Locum Partners LP, has voting or investment control over the securities held by each
of Tri Locum Master Fund, New Holland and MSTV I. The address of each of Tri Locum Master Fund, New Holland and MSTV I is c/o Tri Locum Partners LP, 287 Park Avenue South, 2nd Floor, New York, NY 10010. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#147;Shares of Common Stock Beneficially Owned Prior to the Offering&#148; consist
of (i) 2,350,000 shares of Common Stock purchased by CVI Investments, Inc. (&#147;CVI&#148;) in the Private Placement, (ii) 37,500 shares of Common Stock issuable upon the exercise of our Class&nbsp;A warrants held by CVI and (iii) 2,272,727 shares
of Common Stock issuable upon the exercise of our Class&nbsp;C warrants held by CVI. Heights Capital Management, Inc., the authorized agent of CVI, has discretionary authority to vote and dispose of the shares held by CVI and may be deemed to be the
beneficial owner of these shares. Martin Kobinger, in his capacity as Investment Manager of Heights Capital Management, Inc., may also be deemed </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
to have investment discretion and voting power over the shares held by CVI. Mr.&nbsp;Kobinger disclaims any such beneficial ownership of the shares. CVI is affiliated with one or more FINRA
members, none of whom is currently expected to participate in the sale pursuant to this prospectus. The address of CVI is c/o Heights Capital Management, Inc., 101California Street, Suite 3250, San Francisco, CA 94111. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#147;Shares of Common Stock Beneficially Owned Prior to the Offering&#148; represent
4,605,263 shares of Common Stock purchased in the Private Placement. The shares held by Stonepine Capital, LP may be deemed to be beneficially owned by Jon Plexico and Tim Lynch. Each of Mr.&nbsp;Plexico and Mr.&nbsp;Lynch disclaims beneficial
ownership of the securities except to the extent of their respective pecuniary interests therein. The address of Stonepine Capital, LP is c/o Stonepine Capital Management, 919 NW Bond Street, Suite 204, Bend OR 97703. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#147;Shares of Common Stock Beneficially Owned Prior to the Offering&#148; represent
4,276,315 shares of Common Stock purchased in the Private Placement. Adage Capital Management, L.P. has investment control over the securities held by Adage Capital Partners LP. Bob Atchinson and Phillip Gross are the managing members of Adage
Capital Advisors, L.L.C., which is the managing member of Adage Capital Partners GP, L.L.C., which is the general partner of Adage Capital Management, L.P., and each such person or entity, as the case may be, has shared voting and/or investment
power over the securities held by Adage Capital Partners, LP and may be deemed the beneficial owner of such shares, and each such person or entity, as the case may be, disclaims beneficial ownership of such securities except to the extent of their
respective pecuniary interest therein. The address of Adage Capital Partners LP is 200 Clarendon Street, 52nd Floor, Boston, MA 02116. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#147;Shares of Common Stock Beneficially Owned Prior to the Offering&#148; consist
of (i) 909,350 shares of Common Stock purchased in the Private Placement, (ii) 1,909,409 additional shares of Common Stock previously purchased and (iii) 612,824 shares of Common Stock issuable upon exercise of certain warrants previously purchased.
The shares held by Schonfeld EXT Master Fund LP may be deemed to be beneficially owned by Gregory Martinez. Mr.&nbsp;Martinez disclaims beneficial ownership of the securities except to the extent of his pecuniary interests therein. The address of
Schonfeld EXT Master Fund LP is 590 Madison Ave, 23rd Floor, New York, NY 10022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#147;Shares of Common Stock Beneficially Owned Prior to the Offering&#148; consist
of (i) 340,650 shares of Common Stock purchased in the Private Placement, (ii) 712,184 additional shares of Common Stock previously purchased and (iii) 524,352 shares of Common Stock issuable upon exercise of certain warrants previously purchased.
The shares held by Parkman HP Master Fund LP may be deemed to be beneficially owned by Gregory Martinez, Managing Member, GP of Parkman HP Master Fund LP. Mr.&nbsp;Martinez disclaims beneficial ownership of the securities except to the extent of his
pecuniary interests therein. The address of Parkman HP Master Fund LP is 700 Canal Street, 2nd Floor, Stamford, CT 06902. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#147;Shares of Common Stock Beneficially Owned Prior to the Offering&#148; consist
of (i) 657,894 shares of Common Stock purchased in the Private Placement, (ii) 130,000 additional shares of Common Stock previously purchased and (iii) 1,363,636 shares of Common Stock issuable upon exercise of certain warrants previously purchased.
Laurence Lytton has voting and investment control over the shares of Common Stock held by the Lytton-Kambara Foundation. The address of the Lytton-Kambara Foundation is c/o Laurence Lytton, 467 Central Park West, 17A, New York, NY 10025.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(16)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#147;Shares of Common Stock Beneficially Owned Prior to the Offering&#148; represent
3,000,000 shares of Common Stock purchased in the Private Placement. Citadel Advisors LLC is the portfolio manager of Citadel CEMF Investments Ltd. Citadel Advisors Holdings LP is the sole member of Citadel Advisors LLC. Citadel GP LLC is the
General Partner of Citadel Advisors Holdings LP. Kenneth Griffin owns a controlling interest in Citadel GP LLC. Mr.&nbsp;Griffin, as the owner of a controlling interest in Citadel GP LLC, may be deemed to have shared power to vote and/or shared
power to dispose of the securities held by Citadel CEMF Investments Ltd. This disclosure shall not be construed as an admission that Mr.&nbsp;Griffin or any of the Citadel related entities listed above is the beneficial owner of any of our
securities other than the securities actually owned by such person (if any). The address of Citadel CEMF Investments Ltd. is Southeast Financial Center, 200 S. Biscayne Blvd., Suite 3300, Miami, FL 33131. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(17)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#147;Shares of Common Stock Beneficially Owned Prior to the Offering&#148; consist
of (i) 1,677,631 shares of Common Stock purchased by M. Kingdon Offshore Master Fund, LP in the Private </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Placement and (ii) 296,052 shares of Common Stock purchased by Kingdon Healthcare Master Fund, LP in the Private Placement. Mark Kingdon, as the managing member of Kingdon GP, LLC and Kingdon GP
II, LLC, which is the general partner of M. Kingdon Offshore Master Fund, LP and Kingdon Healthcare Master Fund, LP, respectively, has voting or investment control over the securities held by M. Kingdon Offshore Master Fund, LP and Kingdon
Healthcare Master Fund, LP. The address of M. Kingdon Offshore Master Fund, LP and Kingdon Healthcare Master Fund, LP, respectively is c/o Kingdon Capital Management, LLC, 152 W. 57th Street, 50th Floor, New York, NY 10019. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Relationships with Selling Stockholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As discussed in greater detail above under the section titled &#147;<I>Prospectus Summary&#151;Private Placement</I>,&#148; in May 2023, we
entered into the Purchase Agreement with the Selling Stockholders, pursuant to which we sold and issued shares of our Common Stock and <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to purchase our Common Stock. We also entered into the
Registration Rights Agreement with the Selling Stockholders, pursuant to which we agreed to file a registration statement with the SEC to cover the resale by the Selling Stockholders of the shares of our Common Stock, including the shares of Common
Stock issuable upon exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, issued pursuant to the Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the Selling Stockholders has had a material relationship with us or any of our predecessors or affiliates within the past three years,
other than as a result of the ownership of our shares of Common Stock or other securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the Selling Stockholders has held any
position or office with us or our affiliates within the last three years. Carl Gordon, who serves on the investment committee of OrbiMed Advisors, served on the Board of Directors of Arsanis, Inc., our predecessor, from 2010 to March&nbsp;13, 2019.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc2418143_8"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Stockholders, which as used herein includes donees, pledgees, transferees or other <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> selling shares of Common Stock or interests in shares of Common Stock received after the date of this prospectus from a Selling Stockholder as a gift, pledge, partnership distribution
or other transfer, may, from time to time, sell, transfer or otherwise dispose of any or all of their shares of Common Stock or interests in shares of Common Stock on any stock exchange, market or trading facility on which the shares are traded or
in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Stockholders may use any one or more of the following methods when disposing of shares or interests therein: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a
portion of the block as principal to facilitate the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exchange distribution in accordance with the rules of the applicable exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">privately negotiated transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">distributions to members, partners, stockholders or other equityholders of the selling stockholders;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">short sales effected after the date the registration statement of which this prospectus is a part is declared
effective by the SEC; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through the writing or settlement of options or other hedging transactions, whether through an options exchange
or otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">broker-dealers may agree with the Selling Stockholders to sell a specified number of such shares at a stipulated
price per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a combination of any such methods of sale; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other method permitted by applicable law. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Stockholders may, from time to time, pledge or grant a security interest in some or all of the shares of Common Stock owned by
them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of Common Stock, from time to time, under this prospectus, or under an amendment to this prospectus under Rule
424(b)(3), under Rule 144 or other applicable provision of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), amending the list of Selling Stockholders to include the pledgee, transferee or other successors in interest as
Selling Stockholders under this prospectus. The Selling Stockholders also may transfer the shares of Common Stock in other circumstances, in which case the transferees, pledgees, donees or other successors in interest will be the selling beneficial
owners for purposes of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the sale of our Common Stock or interests therein, the Selling Stockholders
may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the Common Stock in the course of hedging the positions they assume. The Selling Stockholders may also sell shares of
our Common Stock short and deliver these securities to close out their short positions, or loan or pledge the Common Stock to broker-dealers that in turn may sell these securities. The Selling Stockholders may also enter into option or other
transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares
such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate proceeds to the Selling Stockholders from the sale of the Common Stock offered
by them will be the purchase price of the Common Stock less discounts or commissions, if any. Each of the Selling Stockholders reserves the right to accept and, together with their agents from time to time, to reject, in whole or in part, any
proposed purchase of Common Stock to be made directly or through agents. We will not receive any of the proceeds from this offering. Upon any exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants by payment of cash, however, we
will receive the exercise price of $0.001 per share pursuant to the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Selling Stockholders also may resell all or a portion of the shares in open market transactions in reliance upon Rule 144 under the Securities Act, provided that the Selling Stockholders meet the criteria and conforms to the requirements of that
rule. A Selling Stockholder that is an entity may elect to make an <FONT STYLE="white-space:nowrap">in-kind</FONT> distribution of shares of Common Stock to its members, partners, stockholders or other equityholders pursuant to the registration
statement of which this prospectus forms a part by delivering a prospectus. To the extent that such members, partners, stockholders or other equityholders are not affiliates of ours, such members, partners, stockholders or other equityholders would
thereby receive freely tradable shares of Common Stock pursuant to a distribution pursuant to the registration statement of which this prospectus forms a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent required, the shares of our Common Stock to be sold, the names of the Selling Stockholders, the respective purchase prices and
public offering prices, the names of any agents or dealers, and any applicable commissions or discounts with respect to a particular offer will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to
the registration statement that includes this prospectus. Selling Stockholders are not obligated to notify the Company of any changes to the number of securities held or owned by the Selling Stockholders or their affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to comply with the securities laws of some states, if applicable, the Common Stock may be sold in these jurisdictions only through
registered or licensed brokers or dealers. In addition, in some states the Common Stock may not be sold unless it has been registered or qualified for sale or an exemption from registration or qualification requirements is available and is complied
with. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have advised the Selling Stockholders that the anti-manipulation rules of Regulation M under the Securities Exchange Act of
1934, as amended, may apply to sales of shares in the market and to the activities of the Selling Stockholders and their affiliates. In addition, to the extent applicable, we will make copies of this prospectus (as it may be supplemented or amended
from time to time) available to the Selling Stockholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The Selling Stockholders may indemnify any broker-dealer that participates in transactions involving
the sale of the shares against certain liabilities, including liabilities arising under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify
the Selling Stockholders against liabilities, including liabilities under the Securities Act and state securities laws, relating to the registration of the shares offered by this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed with the Selling Stockholders to use commercially reasonable efforts to cause the registration statement of which this
prospectus constitutes a part effective and to remain continuously effective until the earlier of (1)&nbsp;such time as all of the shares covered by this prospectus have been disposed of pursuant to and in accordance with such registration statement
or (2)&nbsp;the date on which all of the shares may be sold without restriction pursuant to Rule 144 of the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc2418143_9"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the Shares to be offered for resale by the Selling Stockholders under this prospectus will be passed upon for us by Cooley
LLP, New York, New York. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc2418143_10"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements incorporated in this prospectus by reference to the Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2022 have been so incorporated in reliance on the report (which contains an explanatory paragraph relating to the Company&#146;s ability to continue as a going concern
as described in Note 1 to the financial statements) of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc2418143_11"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we filed with the SEC. This prospectus omits some information contained in the
registration statement in accordance with SEC rules and regulations. You should review the information and exhibits in the registration statement for further information about us and our consolidated subsidiaries and our securities. Statements in
this prospectus concerning any document we filed as an exhibit to the registration statement or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified by reference to these filings. You should review the complete
document to evaluate these statements. You can obtain a copy of the registration statement from the SEC&#146;s website. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file annual,
quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC&#146;s website at http://www.sec.gov. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We make available, free of charge, through our investor relations website, our Annual Reports on Form
<FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> statements of changes in beneficial ownership of securities
and amendments to those reports and statements as soon as reasonably practicable after they are filed with the SEC. The address for our website is www.x4pharma.com. Information contained in or accessible through our website does not constitute a
part of this prospectus and is not incorporated by reference in this prospectus. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc2418143_12"></A>INCORPORATION OF CERTAIN
INFORMATION BY REFERENCE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; information into this prospectus, which means that
we can disclose important information to you by referring you to another document filed separately with the SEC. The SEC file number for the documents incorporated by reference in this prospectus is <FONT STYLE="white-space:nowrap">001-38295.</FONT>
The documents incorporated by reference into this prospectus contain important information that you should read about us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
documents are incorporated by reference into this document: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1501697/000162828023008745/xfor-20221231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the fiscal year ended December&nbsp;31, 2022 (the &#147;2022 Annual Report&#148;), filed with the SEC on March&nbsp;21, 2023, including the information specifically incorporated by reference in
the 2022 Annual Report from our <A HREF="http://www.sec.gov/Archives/edgar/data/1501697/000162828023012932/a2023def14a.htm">definitive proxy statement</A> for the 2023 Annual Meeting of Stockholders, filed with the SEC on April&nbsp;25, 2023, as
supplemented by a <A HREF="http://www.sec.gov/Archives/edgar/data/1501697/000162828023013590/a2023def14aa.htm">supplemental proxy statement</A> for the 2023 Annual Meeting of Stockholders, filed with the SEC on April&nbsp;27, 2023;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1501697/000162828023015763/xfor-20230331.htm">Form
 <FONT STYLE="white-space:nowrap">10-Q</FONT></A> for the fiscal quarter ended March&nbsp;31, 2023, filed with the SEC on May&nbsp;4, 2023; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1501697/000162828023000666/xfor-20230106.htm">January&nbsp;6,
 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1501697/000162828023007516/xfor-20230310.htm">March&nbsp;
10, 2023</A>, and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1501697/000162828023018424/xfor-20230515.htm">May&nbsp;16, 2023</A> (in each case, except for information contained therein which is furnished
rather than filed); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The description of our Common Stock set forth in the registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1501697/000119312517343308/d450669d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A> registering our Common Stock under Section&nbsp;12 of the Exchange Act, which was filed with the SEC on November&nbsp;15, 2017, including any amendments or reports filed for purposes of updating such
description, including <A HREF="http://www.sec.gov/Archives/edgar/data/1501697/000162828023008745/ex_417mar212023.htm">Exhibit 4.17</A> to the 2022 Annual Report. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also incorporate by reference into this prospectus all documents (other than current reports furnished under Item 2.02 or Item 7.01 of Form
<FONT STYLE="white-space:nowrap">8-K</FONT> and exhibits filed on such form that are related to such items) that are filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (i)&nbsp;after the date of the initial
filing of the registration statement of which this prospectus forms a part and prior to effectiveness of the registration statement, or (ii)&nbsp;after the date of this prospectus but prior to the termination of the offering. These documents include
periodic reports, such as Annual Reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> as well as
proxy statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will provide to each person, including any beneficial owner, to whom a prospectus is delivered, without charge upon
written or oral request, a copy of any or all of the documents that are incorporated by reference into this prospectus but not delivered with the prospectus, including exhibits that are specifically incorporated by reference into such documents. You
should direct any requests for documents to X4 Pharmaceuticals, Inc., Attn: Investor Relations, 61 North Beacon Street, 4th Floor, Boston, Massachusetts 02134. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any statement contained in this prospectus or contained in a document incorporated or deemed to be incorporated by reference into this
prospectus will be deemed to be modified or superseded to the extent that a statement contained in this prospectus or any subsequently filed supplement to this prospectus, or document deemed to be incorporated by reference into this prospectus,
modifies or supersedes such statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>42,784,203 Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:70pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g418143g93w91.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:80pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:80pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>June&nbsp;20, 2023 </B></P>
<P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g418143g93w91.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g418143g93w91.jpg
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M 0'_P  1" !& '$# 1$  A$! Q$!_\0 '@   @(" P$!            "0H
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MITY(D+=LW )*BF.<RT""(:5$(124(3E2L8S*V955F9@JJ"S,Q 55 R68G
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M&2$7C&IX(H&TOVP"_P"7I/\ RQG_ *UZ8_@^_P"+_P" _P#-UZ_X:3_-L?\
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M[V>?;[OI9XY^WW.$G;Y\.//@_'.>+8P2V_M@%_R])_Y8S_UKU /P??\ %_\
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M7CW(6XE895XX"B-6.?3TIZYZ=FZ:ZCKVH-SHQ*]'<9Z\JO(L8X0VEDE5>=F
ML(;498-9@?GR+M,\8A[[H#;NN[A/TN<HEF<2,!(%9%>1,%+R43("QC!&LC&/
MV[)0G3!^U6%VU+CTD[14H.(+A!0CG]7==OMUXK,5J$)*@8+)+&DBGY,CHS95
MT8%6'D9!P2,$AC<.G=YVR[9HV-OM-+6D,;/#!-+#(/FDL4BQX>*1"KHW@\6
M958%1B'TTV/_  _NW]JSO^!TX];3_2ZW]O%_GTS]V;E^KKW]TL?Z>I]--C_P
M_NW]JSO^!TO6T_TNM_;Q?Y]+W9N7ZNO?W2Q_IZQ!TU=,7+AD];'9O&ABMG31
MT$C=RV<!6H9@. %2@H3!(E0RB(A*QK2I*TX5C..G"LK*&4AE8!E92"K*1D$$
M>""/((\$>1IFZ/&S(ZLCHQ5T=2K*RG#*RD JP((((!!&"-1LV<O7#=FS;G=N
MW1A-FK5L(AW#EP=:1! W )*RF,8BDC$(:5+(M24(3E6<8RB0H+,0JJ"68D
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MI</VV 5AX1F;.5"\E8#DN\;:]>M:6TA@N6%JUGX2CNV'9D6,(4#J2RD<G55
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>?LZ[^[2ZTZ9_./I_]M[5^_U]-U] #5S=3I:6O__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
